Almirall 9M 2026 Results
Almirall reported first-nine-month 2026 net sales of €889.2 million, up 8.3% year over year, and EBITDA of €221.7 million, up 22.7%. It reiterated its full-year 2026 guidance, citing steady performance and growth in European Dermatology.
Why it matters — The item concerns Almirall, S.A. (ALM), a pharmaceutical company, and does not identify Almonty Industries, Inc. as the subject.